1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. LITE STRATEGY INC.
Lite Strategy Inc.
XNAS: LITS
1.22-0.05(-3.94%)
256.9K
XNAS Volume

XNAS 12 Oct, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

MEI Pharma Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

MEI Pharma Inc quarterly results: revenue, profit, and P&L – 13 quarter history

  • NEUTRAL

    Quarterly Revenue MEI Pharma Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

  • NEGATIVE

    Quarterly Net Profit MEI Pharma Inc Jun-2026 Quarterly Net Profit is $-13 Million which is growth of -384.3% YoY.

Lite Strategy Inc., Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
65.31.5
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
-2.92.83.43.12.92.83.58.48.19.811.91012.5
Operating Profit
-2.9-2.8-3.4-3.1-2.9-2.8-3.5-8.4-8.1-9.8-11.955.3-11.1
0.10.10.10.10.20.20.30.40.60.70.91.11.1
Profit Before Tax
-13-23.7-30.8-3.6-2.7-2.6-2.7-8-18.4-9.1-11.156.4-10
Tax
-------------
⌄
-13-23.7-30.8-3.6-2.7-2.6-2.7-8-18.4-9.1-11.156.4-10
Diluted NI Avail to Com Stockholders Ann.
-13-23.7-30.8-3.6-2.7-2.6-2.7-8-18.4-9.1-11.156.4-10
Basic EPS
-0.4-0.7-0.8-0.1-0.4-0.4-0.4-1.2-2.8-1.4-1.78.5-1.5
Diluted EPS After ExtraOrdinary
--0.1-0.1-0.1-0.4-0.4-0.5-1.2-2.8-1.4-1.78.5-1.5
Number Of Shares End
34.635.737.429.56.76.76.76.76.76.76.76.76.7
Net Income Continuing Discontinued Operations
-13-23.7-30.8-3.6-2.7-2.6-2.7-8-18.4-9.1-11.156.4-10
Normalized Income
-2.4-2.4-2.5-2.7-2.6-2.6-3.3-8.1-7.1-8.5-10.256.7-10
Interest Income
0.10.10.10.10.20.20.30.40.60.70.91.11.1
Interest
-------------
Net Interest Income
-0.10.10.10.20.20.30.40.60.70.91.11.1
EBIT
-13.1-23.8-30.9-3.7-2.9-2.8-3-8.4-19-9.8-11.955.3-11.1
EBITDA
-13.1-23.8-30.9-3.7-2.9-2.8-3-8-18.9-9.8-11.955.4-11
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
-0.40.10.10.10.10.1
Profit From Continuing Operations
-13-23.7-30.8-3.6-2.7-2.6-2.7-8-18.4-9.1-11.156.4-10
Normalized EBITDA
-18.224.2-2.5-2.9-2.8-4-8-8-9.7-11.955.4-11
*All financials are in USD Million and price data in USD

MEI Pharma Inc competitor comparison and performance snapshot within industry

MEI Pharma Inc annual results: revenue, profit, P&L, and margins as of Jun 2026 – 11 year history

  • NEUTRAL

    Annual Revenue MEI Pharma Inc Annual Revenue is $0 Million which is growth of 0% YoY.

  • NEGATIVE

    Annual Net Profit MEI Pharma Inc Annual Net Profit is $-71 Million which is growth of -346.2% YoY.

Lite Strategy Inc., Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMJun '26Jun '25Jun '24Jun '23Jun '22Jun '21Jun '20Jun '19Jun '18Jun '17Jun '16
-
-
 65.348.840.725.528.94.91.623.3
Cost Of Rev. Ann.
-
-
 ----1.42.74.33.45-
Gross Profit Ann.
-
-
 ----40.724.126.20.7-1.818.3-
Operating Exp. Ann.
-
-
6.3-12.217.539.985.6116.293.850.846.926.815.921
Operating Profit Ann.
-
-
-12.2-12.2-17.525.4-36.8-75.5-69.7-24.5-46.2-28.62.4-21
-55.5%
-9.7%
0.30.313.33.40.30.51.41.8-1.80.30.1
Other Exp. Ann.
-71.1%
-
 0.5-10.91.620.818.6-22.927.6-9.7--
PBT Ann.
-
-
-71.2-71.2-15.917.8-31.8-54.5-50.6-46-16.8-40.12.7-20.9
Tax Ann.
-
-
 ----0
⌄
-
-
-71.1-71.2-1617.8-31.8-54.5-50.6-46-16.8-40.12.7-20.9
Diluted NI Avail to Com Stockholders Ann.
-
-
-71.1-71.2-1617.8-31.8-62.5-78-46-54.6-40.12.7-20.9
EPS Ann.
-
-
 -2.1-2.42.7-4.8-8.8-9-10.2-4.8-19.41.4-12.2
Diluted EPS Ann.
-
-
 -2.1-2.42.7-4.8-10-13.6-10.2-15-19.41.4-12.2
Number Of Shares End
72.8%
43.9%
 34.66.76.76.76.75.65.33.62.71.91.7
Total Exp. Ann.
-
-
 -17.539.985.6116.295.253.551.230.220.921
Net Income Continuing Discontinued Operations Ann.
-
-
-71.1-71.2-1617.8-31.8-54.5-50.6-46-16.8-40.12.7-20.9
Normalized Income Ann.
-
-
-10.1-10.6-17.128.2-33.4-66.9-56.3-24.2-32.2-30.65-19.2
Interest Income Ann.
-55.5%
-9.7%
0.30.313.33.40.30.51.41.80.60.30.1
Interest Ann.
-
-
 -----------
EBITDA Ann.
-
-
-71.4-71.4-16.614.9-34.8-54.4-50.8-47.3-18.5-40.62.5-21
Reconciled Cost Of Rev. Ann.
-
-
 ----1.42.74.33.45-
Reconciled Depr. Ann.
-
-
 -0.40.40.40.30.30.10.10.10.10.1
Profit From Continuing Operations Ann.
-
-
-71.1-71.2-15.917.8-31.8-54.5-50.6-46-16.8-40.12.7-20.9
Normalized EBITDA Ann.
-
-
 --17.636.7-38-95.9-87.5-1.6-73.8-18.82.5-21
*All financials are in USD Million and price data in USD

MEI Pharma Inc balance sheet as of Jun 2026: assets, liabilities, reserves, and borrowings – 11 year history

  • NEUTRAL

    Total Shareholders Fund MEI Pharma Inc Total Shareholders Fund is $0 Million which is growth of 0% YoY.

  • NEUTRAL

    Total Assets MEI Pharma Inc Total Assets is $0 Million which is growth of 0% YoY.

Lite Strategy Inc., Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsJun '26Jun '25Jun '24Jun '23Jun '22Jun '21Jun '20Jun '19Jun '18Jun '17Jun '16
-
-
-18.341.4120.8177.8174.1209.782.7104.755.747.2
⌄
-
-
-1.48.496.2125.4132.7131.534.754.24.95.5
⌄
-
-
-16.93324.652.441.478.247.950.550.841.7
Total Capitalization Ann.
-
-
-16.93324.652.441.478.247.950.550.841.7
Tangible Assets Ann.
-
-
-16.93324.652.441.478.247.750.250.541.3
Working Capital Ann.
-
-
-16.932.487.2142.7134.5185.367.996.450.541.2
Invested Capital Ann.
-
-
-16.93324.652.441.478.247.950.550.841.7
Tangible Book Value Ann.
-
-
-16.93324.652.441.478.247.750.250.541.3
Borrowings Ann.
-
-
--12.79.68.3-----
Net Debt Ann.
-
-
-----------
Share Issued Ann.
-
-
-6.76.76.76.75.65.63.73.51.81.7
Number Of Shares End
72.8%
43.9%
34.66.76.76.76.75.65.33.62.71.91.7
*All financials are in USD Million and price data in USD

MEI Pharma Inc ROE, ROCE, book value, and debt-to-equity ratio as of Jun 2026 – 11 year history

  • NEUTRAL

    Book Value Per Share MEI Pharma Inc Book Value Per Share is $0 which is growth of 0% YoY.

  • NEUTRAL

    ROE MEI Pharma Inc ROE is 0% which is growth of 0% YoY.

Lite Strategy Inc., Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsJun '26Jun '25Jun '24Jun '23Jun '22Jun '21Jun '20Jun '19Jun '18Jun '17Jun '16
RoA Ann. %
-
-
--53.45%21.92%-21.32%-30.95%-26.35%-31.48%-17.96%-49.97%5.19%-37.28%
ROE Ann. %
-
-
--63.84%61.68%-82.66%-116.14%-84.59%-72.96%-34.19%-79.11%5.77%-41.13%
ROIC %
-
-
--15.8-40.2-26.2-23.3-11.1-24.66.1-46.9-8.4-13.2
OPM Ann. %
-
-
--38.96%-75.31%-185.48%-272.90%-84.88%-940.90%-1,762.39%10.25%-
Inventory Turnover Ratio Ann.
-
-
-----------
Asset Turnover Ann. %
-
-
--0.80.30.20.10.20.100.5-
Working Capital Turnover Ann.
-
-
-20.60.30.20.20.100.5
Quick Ratio Ann.
-
-
-13.34.656.75.38.75.613118.3
Current Ratio Ann.
-
-
-13.54.95.36.85.495.813.211.48.5
Interest Coverage Ratio Ann.
-
-
-----------
LT Debt To Equity Ann.
-
-
---0.50.20.2-----
*All financials are in USD Million and price data in USD

MEI Pharma Inc cash flow: net, operating, investing, and financing flows as of Jun 2026 – 11 year history

  • POSITIVE

    Cash From Operating Activity MEI Pharma Inc Cash From Operating Activity is $-9 Million which is growth of 56.2% YoY.

  • NEGATIVE

    Net Cash Flow MEI Pharma Inc Net Cash Flow is $-12 Million which is growth of -186.0% YoY.

Lite Strategy Inc., Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsJun '26Jun '25Jun '24Jun '23Jun '22Jun '21Jun '20Jun '19Jun '18Jun '17Jun '16
-
-
-9.1-20.8-50.5-52.5-48.8-3234.3-29.4-21.33.5-17.9
-
-
-95.135.249.153.76.924.7-106.324.3-44.3-10.110
-
92.2%
91.9-11.9-049.13.574.81.470.54.2
Cash Plus Cash Eqv. End Of Year Ann.
-30.4%
-7.7%
5.7183.716.915.78.512.39.613.38.510.8
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-
-12.314.3-13.21.27.2-3.82.7-3.74.9-2.4-7.9
Cash Plus Cash Eqv. Begin Of Year Ann.
4.7%
7.9%
183.716.915.78.512.39.613.38.510.818.7
Income Tax Paid Supplemental Data Ann.
-
-
----0
Interest Paid Supplemental Data Ann.
-
-
-----------
Capex Ann.
-
-
---0-0-0.5-0.7-0.9-0.2--0.1
Issuance Of Capital Stock Ann.
-
-
---52.33.174.50.270.24.2
Issuance Of Debt Ann.
-
-
-----------
Repayment Of Debt Ann.
-
-
-----------
Repurchase Of Capital Stock Ann.
-
-
-----------
Free Cash Flow Ann.
-
-
-9.1-20.8-50.5-52.5-49.2-32.733.4-29.6-21.33.4-17.9
*All financials are in USD Million and price data in USD
Cash from Financing Act. Ann.
5Y CAGR
92.2%
7Y CAGR
81.8%
Cash from Financing Annual Activity growth is higher than historical averages.